We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid Lateral Flow Assays Detect COVID-19 Variants and Differentiate COVID-19 from Other Respiratory Viral Diseases

By LabMedica International staff writers
Posted on 02 Mar 2021
A recent publication reported the development of two rapid diagnostic tests - one that detects COVID-19 variants and one that differentiates COVID-19 from other respiratory viral diseases.

Investigators at the University of Minnesota Medical School (Minneapolis/St.Paul, USA) used the CRISPR/Cas9 gene editing tool to develop two rapid lateral flow diagnostic tests. More...
CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

The investigators integrated commercially available reagents into a CRISPR/Cas9-based lateral flow assay (LFA) that could detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences with single-base specificity. This approach required minimal equipment and represented a simplified platform for field-based deployment. They also developed a rapid, multiplex fluorescence CRISPR/Cas9 nuclease cleavage assay capable of detecting and differentiating SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV) in a single reaction.

The LFA test strips employed bound fluorescein isothiocyanate (FITC)/6-Carboxyfluorescein (FAM) and biotin to generate a positive result. Therefore, the investigators used a FITC/FAM-labeled PCR primer and a nuclease inactive (“dead”) biotinylated Cas9 and a single sgRNA specific for the ORF8a gene of SARS-Co-V-2 to label amplicons for detection by LFA. This approach was capable of single-nucleotide resolution and avoided false positives from primer dimer or non-specific amplification artifacts that could occur with the use of tandem FITC- and biotin-labeled primers for LFA.

"The approval of the SARS-CoV-2 vaccine is highly promising, but the time between first doses and population immunity may be months," said first author Dr. Mark J. Osborn, assistant professor of pediatrics at the University of Minnesota Medical School. "This testing platform can help bridge the gap between immunization and immunity."

The rapid LFA tests were described in the February 12, 2021, online edition of the journal Bioengineering.

Related Links:
University of Minnesota Medical School


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Portable Electronic Pipette
Mini 96
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.